A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma

References

• Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19–iv29.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN. GLOBOCAN 2018: estimated cancer incidence, mortality, and prevalence worldwide in 2018. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1. Cited 2021 Apr 21.
   Google Scholar
• National cancer institute: Surveillance epidemiology, and end results program (SEER). 2021. Cancer stat facts: Hodgkin lymphoma. Available from: https://seer.cancer.gov/statfacts/html/hodg.html. Cited 2021 Apr 21.
   Google Scholar
• Grimm SE, Fayter D, Ramaekers BLT, et al. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: An evidence review group perspective of a nice single technology appraisal. Pharmacoeconomics. 2019;37(10):1195–1207.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. March 2017. Health technology appraisal. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. Available from: https://www.nice.org.uk/guidance/ta540/documents/final-scope. Cited 2021 Apr 21.
   Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Linendoll N, Saunders T, Burns R, et al. Health-related quality of life in Hodgkin lymphoma: a systematic review. Health Qual Life Outcomes. 2016;14(1):114.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Mehta J, Abbe A, Trask PC, et al. Epidemiology projection trends for Hodgkin lymphoma patients in the U.S. and Europe. Blood. 2012;120(21):4782.
   Google Scholar
• Farruggia P, Puccio G, Locatelli F, et al. Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience. Leuk Lymphoma. 2019;60(3):696–702.
   PubMed Web of Science ®Google Scholar
• Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin lymphoma study group. J Clin Oncol. 2005;23(7):1522–1529.
   PubMed Web of Science ®Google Scholar
• Martinez C, Gayoso J, Canals C, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the European society for blood and marrow transplantation. J Clin Oncol. 2017;35(30):3425–3432.
   PubMed Web of Science ®Google Scholar
• Sureda A, Boumendil A, Sieniawski M, et al. Secondary malignancies after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin’s lymphoma. A retrospective analysis on behalf of the lymphoma working party of the European Society for Blood and Marrow Transplantation (EBMT). Blood. 2013;122 (21) :4636.
   Google Scholar
• Myers RM, Hill BT, Shaw BE, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018;124(4):816–825.
   PubMed Web of Science ®Google Scholar
• Dulery R, Reman O, Boumemdil A, et al. Outcome analysis of high-dose chemotherapy followed by autologous stem cell transplantation in patients with Hodgkin lymphoma: A francophone society of bone marrow transplantation and cellular therapy study. Blood. 2016;128(22):3458. DOI:https://doi.org/10.1182/blood.V128.22.3458.3458.
   Google Scholar
• Bröckelmann PJ, Eichenauer DA, Jakob T, et al. Hodgkin lymphoma in adults. Dtsch Arztebl Int. 2018;115(31–32):535–540.
   PubMedGoogle Scholar
• Byrne K, Juarez-Garcia A, Hallworth P, et al. Later line drug treatment patterns of classical Hodgkin’s lymphoma (cHL) patients in Canada, France, Germany and the United Kingdom. Haematologica. 2017;102 e2 :83.
   Google Scholar
• Chen C, Johnston K, Szabo S, et al. Economic burden in US patients with relapsed or refractory classical Hodgkin lymphoma treated with brentuximab vedotin or chemotherapy after failure of autologous hematopoietic cell transplantation. Blood. 2017;130 (Supplement_1) :4705.
   Google Scholar
• Collins GP, Rueda A, Salles G, et al. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma. 2018;59(9):2113–2120.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Nademanee A, Masszi T, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016;175(5):860–867.
   PubMed Web of Science ®Google Scholar
• Szabo SM, Juarez-Garcia A, Johnston KM, et al. Real world treatment patterns among an incident cohort of patients with Hodgkin lymphoma in the United States. Value Health. 2017;20 (5) :A124–A124.
   Google Scholar
• Szabo SM, Hirji I, Johnston KM, et al. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: a retrospective cohort study. PLoS One. 2017;12(10):e0180261.
   PubMed Web of Science ®Google Scholar
• Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin lymphoma study group (GHSG). Eur J Cancer. 2003;39(15):2179–2186.
   PubMedGoogle Scholar
• Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240–5247.
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Anastasia A, Mencaglia M, et al. Psychosocial functioning in Hodgkin’s lymphoma survivors after ifosfamide, gemcitabine, vinorelbine (IGEV) and high-dose chemotherapy with autologous haematopoietic stem cell infusion. Bone Marrow Transplant. 2010;45:S108–S108.
   Google Scholar
• Minn AY, Riedel E, Halpern J, et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. Br J Haematol. 2012;159(3):329–339.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Fanale M, Ardeshna KM, et al. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60(11):2705–2711.
   PubMed Web of Science ®Google Scholar
• Lepik K, Mikhaylova N, Kondakova E, et al. Response to nivolumab as ≥3rd line therapy in pts with relapsed/refractory classical Hodgkin’s lymphoma (cHL) and its impact on quality of life in responders and nonresponders. Hematol Oncol. 2019;37 (Supplement_2) :495.
   Google Scholar
• Kreissl S, Goergen H, Muller H, et al. Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin study group. Leuk Lymphoma. 2019;60(6):1389–1398.
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19.
   PubMed Web of Science ®Google Scholar
• Ionova T, Afanasiev B, Andrievskih M, et al. Response to brentuximab vedotin and quality of life in patients with relapsed/refractory Hodgkin lymphoma (RR HL) in the real world setting. Blood. 2019;134(Supplement_1):5296.
   Google Scholar
• Bonafede M, Feliciano J, Cai Q, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res. 2018;10:629–641.
   PubMed Web of Science ®Google Scholar
• Yasenchak CA, Tseng WY, Yap M, et al. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56(11):3143–3149.
   PubMed Web of Science ®Google Scholar
• Laliberté F, Raut M, Duh M, et al. Real-world healthcare resource utilization (HRU) of classical Hodgkin lymphoma (cHL) patients (PTS) treated with anti-PD1 checkpoint inhibitors in the United States (US). Hematol Oncol. 2019;37:495–496.
   Google Scholar
• Radford J, McKay P, Malladi R, et al. Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. Bone Marrow Transplant. 2017;52(3):452–454.
   PubMedGoogle Scholar
• Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010;116(16):3835–3842.
   PubMed Web of Science ®Google Scholar
• Patel V, Buckstein M, Perini R, et al. Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. Leuk Lymphoma. 2013;54(10):2168–2176.
   PubMed Web of Science ®Google Scholar
• Pingali SR, Jewell SW, Havlat L, et al. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer. 2014;120(14):2122–2129.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica. 2012;97(6):931–936.
   PubMed Web of Science ®Google Scholar
• Large S, Hettle R, Balakumaran A, et al. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective. Med Econ. 2018:1–10. doi:https://doi.org/10.1080/13696998.2018.1534738.
   Google Scholar
• Hui L, von Keudell G, Wang R, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763–3771.
   PubMed Web of Science ®Google Scholar
• Parker C, Woods B, Eaton J, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. J Med Econ. 2017;20(1):8–18.
   PubMed Web of Science ®Google Scholar
• Babashov V, Begen MA, Mangel J. Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. Current Oncol. 2017;24(1):e6.
   PubMed Web of Science ®Google Scholar
• Tan M, Lozano-Ortega G, Szabo S, et al. Cost effectiveness of nivolumab for the treatment of relapsed/refractory classical Hodgkin lymphoma (cHL) after failure of autologous stem cell transplantation (ASCT) and treatment with brentuximab vedotin (BV) treatment in Australia. Blood. 2017;130 (Supplement_1) :2166.
   Google Scholar
• Jones B, Ward T, Harrison J, et al. The cost-effectiveness of nivolumab for the treatment of people with relapsed or refractory classical Hodgkin lymphoma following autologous stem cell transplant and brentuximab vedotin. Value Health. 2017;20(9):A433–A433.
   Google Scholar
• Patidar M, Campbell JD. To evaluate the cost-effectiveness of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma who have received chemotherapy/chemotherapy with stem cell transplantation as first line therapy from a US healthcare perspective. Value Health. 2017;20 (5) :A359–A359.
   Google Scholar
• Romero Prada ME, Roa Cardenas NC, Vasquez Melo EC, et al. Cost-effectiveness of using brentuximab vedotin in patients with recurrent Hodgkin lymphoma or refractory to transplant. Value Health. 2016;19(7):A733.
   Google Scholar
• Khachatryan GR, Fedyaev DV, Avxentyeva MV. Cost-effectiveness analysis of brentuximab vedotin in adults with relapsed or refractory Hodgkin’s lymphoma. Value Health. 2016;19 (7) :A734.
   PubMedGoogle Scholar
• Ringkvist J Engstrom, A. The cost-effectiveness of brentuximab vedotin as consolidation treatment after autologous stem-cell transplantation in patients with Hodgkin lymphoma and increased risk of relapse. Value Health. 2017;20(9):A437.
   Google Scholar
• NCCN National Comprehensive Cancer Network®. Clinical practice guidelines in oncology (NCCN guidelines). Hodgkin Lymphoma. 2020; Version 1.2020.
   Google Scholar
• Perales MA, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971–983.
   PubMed Web of Science ®Google Scholar
• Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1005–1013.
   PubMedGoogle Scholar
• Eccersley L, Iyengar S, Townsend W, et al. Pan London haemato-oncology clinical guidelines. Lymphoid malignancies. part 1: Hodgkin lymphoma. January 2020. RM Partners West London Cancer Alliance. SELCA. South East London Cancer Alliance. NHS North Central and East London Cancer Alliance; https://rmpartners.nhs.uk/wp-content/uploads/2020/01/Pan-London-Hodgkin-Guidelines-Jan-2020.pdf Accessed 21 April 2021.
   Google Scholar
• Badar T, Epperla N, Szabo A, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):47–54.
   PubMed Web of Science ®Google Scholar
• Shao C, Liu J, Zhou W, et al. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2019;60(4):947–954.
   PubMed Web of Science ®Google Scholar
• Gajra A, Klink AJ, Nabhan C. Utilization of immune checkpoint inhibitors for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in oncology community practices. Blood. 2019;134(Supplement_1):4057.
   Google Scholar
• Feliciano J, Way N, Engley G, et al. Real world evidence in relapsed/refractory classical Hodgkin lymphoma patients who are ineligible for stem cell transplant in the United States (US). Blood. 2018;132(Supplement 1):2268.
   Google Scholar
• Gerrie AS, Power MM, Shepherd JD, et al. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Ann Oncol. 2014;25(11) :2218–2223.
   PubMedGoogle Scholar
• Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–163.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol. 2013;50(1):4–14.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst. 2008;100(24):1763–1770.
   PubMedGoogle Scholar